Latest Breaking News On - Index pharmaceuticals holding - Page 2 : comparemela.com

InDex Pharmaceuticals discontinues cobitolimod phase III program

/PRNewswire/ InDex Pharmaceuticals Holding AB (publ) ("InDex Pharmaceuticals") today announces that an independent DMC has completed the planned dose.

Johan gilJenny sundqvistData monitoring committeeKindex pharmaceuticalsPrnewswire index pharmaceuticals holdingIndex pharmaceuticals holdingIndependent data monitoring committeeInduction studyAbuse regulationDex pharmaceuticalsNasdaq first north growth market

InDex Pharmaceuticals discontinues cobitolimod phase III program

STOCKHOLM, Nov. 21, 2023 /PRNewswire/ InDex Pharmaceuticals Holding AB (publ) ("InDex Pharmaceuticals").

Johan gilJenny sundqvistKindex pharmaceuticalsData monitoring committeeIndex pharmaceuticals holdingPrnewswire index pharmaceuticals holdingInduction studyAbuse regulationDex pharmaceuticalsNasdaq first north growth market

InDex Pharmaceuticals discontinues cobitolimod phase III program

/PRNewswire/ InDex Pharmaceuticals Holding AB (publ) ("InDex Pharmaceuticals") today announces that an independent DMC has completed the planned dose.

Jenny sundqvistJohan gilPrnewswire index pharmaceuticals holdingData monitoring committeeKindex pharmaceuticalsIndex pharmaceuticals holdingIndependent data monitoring committeeInduction studyAbuse regulationDex pharmaceuticalsNasdaq first north growth market

InDex Pharmaceuticals discontinues cobitolimod phase III program

InDex Pharmaceuticals discontinues cobitolimod phase III program
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Rheinland pfalzJenny sundqvistJohan gilData monitoring committeeKindex pharmaceuticalsIndex pharmaceuticals holdingPrnewswire index pharmaceuticals holdingIndependent data monitoring committeeInduction studyAbuse regulationDex pharmaceuticalsNasdaq first north growth market

InDex Pharmaceuticals has been granted a new patent in Europe for the commercial formulation of cobitolimod

/PRNewswire/ InDex Pharmaceuticals Holding AB (publ) today announced that a new formulation patent for the drug candidate cobitolimod has been granted by.

Johan gilJenny sundqvistPrnewswire index pharmaceuticals holdingKindex pharmaceuticalsIndex pharmaceuticals holdingEuropean patent officeEuropean patentDex pharmaceuticalsAbuse regulationImmunomodulatory sequencesNasdaq first north growth marketAddex pharma